0000064803-22-000018.txt : 20220516 0000064803-22-000018.hdr.sgml : 20220516 20220516164028 ACCESSION NUMBER: 0000064803-22-000018 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220511 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 22930121 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 cvs-20220511.htm 8-K cvs-20220511
0000064803false00000648032022-05-112022-05-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):May 11, 2022
cvs-20220511_g1.jpg
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-0101105-0494040
(State or other jurisdiction of incorporation)(Commission
File Number)
(IRS Employer
Identification No.)

One CVS Drive, Woonsocket, Rhode Island            02895
(Address of principal executive offices)            (Zip Code)

Registrant’s telephone number, including area code:         (401) 765-1500
Former name or former address, if changed since last report:    N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCVSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Section 5 - Corporate Governance and Management

Item 5.07 Submission of Matters to a Vote of Security Holders.
The following are the voting results on each matter submitted to the stockholders of CVS Health Corporation (the “Company”) at the Annual Meeting of Stockholders held on May 11, 2022 (the “Annual Meeting”). The proposals below are described in detail in the proxy statement filed by the Company on April 1, 2022 (the “Proxy Statement”). There were present at the Annual Meeting, in person or by valid proxy, the holders of 1,139,788,473 shares of the Company’s common stock, constituting a quorum.
At the Annual Meeting, 11 nominees for director were elected to the Company’s Board of Directors for a term of one year (Item 1). The Company proposal regarding the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2022 (Item 2) was approved. The Company proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement (Item 3) was approved. Five stockholder proposals (Items 4, 5, 6, 7, and 8) were not approved.

ItemForAgainstAbstainedBroker Non-Votes
1.The election, for one-year terms, of persons nominated for election as directors of the Company, as set forth in the Company’s Proxy Statement, was approved by the following votes:
Fernando Aguirre980,147,086 4,942,589 2,361,204 152,337,594 
C. David Brown II921,004,907 64,110,649 2,335,323 152,337,594 
Alecia A. DeCoudreaux981,033,116 4,151,581 2,266,182 152,337,594 
Nancy-Ann M. DeParle972,420,338 12,943,153 2,087,388 152,337,594 
Roger N. Farah969,456,061 15,758,278 2,236,540 152,337,594 
Anne M. Finucane961,929,331 23,425,711 2,095,837 152,337,594 
Edward J. Ludwig974,606,439 10,568,872 2,275,568 152,337,594 
Karen S. Lynch978,273,848 7,721,357 1,455,674 152,337,594 
Jean-Pierre Millon953,549,562 31,648,123 2,253,194 152,337,594 
Mary L. Schapiro981,394,995 3,978,425 2,077,459 152,337,594 
William C. Weldon972,634,619 12,527,031 2,289,229 152,337,594 
2.Company proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2022, as set forth in the Company’s Proxy Statement, was approved by the following vote:1,116,442,556 20,830,100 2,515,817 None
3.Company proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers, as set forth in the Company’s Proxy Statement, was approved by the following vote:903,024,507 80,791,141 3,635,231 152,337,594 
4.
Stockholder proposal for reducing the Company’s ownership threshold to request a special stockholder meeting, as set forth in the Company’s Proxy Statement, was not approved by the following vote:
417,733,556 566,063,103 3,654,220 152,337,594 
5.Stockholder proposal regarding the Company’s independent Board Chair, as set forth in the Company’s Proxy Statement, was not approved by the following vote:210,689,771 767,744,358 9,016,750 152,337,594 
6.
Stockholder proposal on a civil rights and non-discrimination audit focused on “non-diverse” employees, as set forth in the Company’s Proxy Statement, was not approved by the following vote:
15,848,267 956,586,591 15,016,021 152,337,594 
7.
Stockholder proposal requesting paid sick leave for all employees, as set forth in the Company’s Proxy Statement, was not approved by the following vote:
255,627,021 719,860,486 11,963,372 152,337,594 
8.
Stockholder proposal regarding a report on the public health costs of the Company’s food business to diversified portfolios, as set forth in the Company’s Proxy Statement, was not approved by the following vote:
116,708,035 854,020,238 16,722,606 152,337,594 
1


Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d)        Exhibits.

The exhibit to this Current Report on Form 8-K is as follows:

INDEX TO EXHIBIT
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CVS HEALTH CORPORATION
Date: May 16, 2022By:/s/ Colleen M. McIntosh
Colleen M. McIntosh
Senior Vice President, Corporate Secretary
and Chief Governance Officer


EX-101.SCH 2 cvs-20220511.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 cvs-20220511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, Address Line One Entity Address, Address Line One Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Written Communications Written Communications Local Phone Number Local Phone Number Soliciting Material Soliciting Material Entity Address, State or Province Entity Address, State or Province City Area Code City Area Code Document Type Document Type Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Address, City or Town Entity Address, City or Town Entity Central Index Key Entity Central Index Key Pre-commencement Tender Offer Pre-commencement Tender Offer Entity File Number Entity File Number Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code EX-101.PRE 4 cvs-20220511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 5 cvs-20220511_g1.jpg CVS HEALTH LOGO begin 644 cvs-20220511_g1.jpg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htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page
May 11, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 11, 2022
Entity Registrant Name CVS HEALTH CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-01011
Entity Tax Identification Number 05-0494040
Entity Address, Address Line One One CVS Drive
Entity Address, City or Town Woonsocket
Entity Address, State or Province RI
Entity Address, Postal Zip Code 02895
City Area Code 401
Local Phone Number 765-1500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol CVS
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000064803
Amendment Flag false
XML 7 cvs-20220511_htm.xml IDEA: XBRL DOCUMENT 0000064803 2022-05-11 2022-05-11 0000064803 false 8-K 2022-05-11 CVS HEALTH CORPORATION DE 001-01011 05-0494040 One CVS Drive Woonsocket RI 02895 401 765-1500 false false false false Common Stock, par value $0.01 per share CVS NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( V%L%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " -A;!4VA)/WN\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>.LV@AZCK91,GD)"8!.(6)=X6K?FCQ*C=V].6K1."!^ 8^Y?/ MGR4W.DH=$KZD$#&1Q7PWN,YGJ>.:'8FB!,CZB$[EF3 M.B (SFMP2,HH4C !B[@06=L8+75"12%=\$8O^/B9NAEF-&"'#CUEJ,H*6#M- MC.>A:^ &F&"$R>7O IJ%.%?_Q,X=8)?DD.V2ZON^[%=S;MRA@O?GI]=YW<+Z M3,IK'']E*^D<<RY%_3&Y_O"[";M@[-[^ M8^.K8-O K[MHOP!02P,$% @ #86P5)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" -A;!4?R4&^2P$ M$ & 'AL+W=OLY40EKPGLEX4KD?#L M3*="P9.%-@FWT#1++TN-X%$1E,2>3^F%EW"I6KUN<6]L>EV=VU@J,38DRY.$ MF\V-B/7ZNL5:'SJ1+)1*A,:D6,6%RW^NSK MC1^X@.*-'U*LL[UKXKHRU_K5-4;1=8LZ(A&+T#H)#A]O8B#BV"D!Q[\[T5;Y MG2YP__I#_:[H/'1FSC,QT/&+C.SJNM5ID4@L>![;B5[?BUV'VDXOU'%6_"?K M[;M!T")AGEF=[(*!()%J^\G?=XG8#Z ' OQ=@%]P;[^HH+SEEO>Z1J^)<6^# MFKLHNEI$ YQ4;E2FUL!3"7&V-]!OPI Q#$#7LZ#G[GKA+O9F&^L?B'WD&\+8 M"?&I[_\_V@.*$L4O4?Q"[AQ%^;L_SZR!P?H'D3PO)<\+R>" Y*T.F#@37 MH)2=4D890W@Z)4_G&)X9?R>C"&:=7,BP2!M"ARO2]BD-K@(:4 3OJL2[.@:O M'T5&9-G)QP5Y@/?(LZH=15P1@HB;?[<&[!TA9+2R1/HIQH%KP6R;Z;6J=4E< M[D5KE>GP55B,;L^PV:?HRF(8&_TF55AOY+CF9(2A50;._$^AC75F>4S^DNG! M"FU0I'[GJHVQ52L!P[V\&,0^;%P.H^ " <7*DU6K <--_$&'D)/Q2BO,,!I$ M+B_:IZQ-L8IDU2+ TSW)JG.I:A MM%(MR2-,;R-Y7,N#JS3R5";/<(<>&W$:0GH$U-=V0R%4!+N5Y\7BP/CA>HUD ME=TSW)U_(AME60YDC8"X;"-@9?@,]^>9M+ TZ@5A_F_SW\E4A#G,MTTM$Z[D MYB>L8U,+9GI"4F[(&X]S07ZE9Y21%'J;K;C!J/UJ#?!QTYX9'KG9-]TD"I>B[N\BZ-!S MC*QR?1\W[#[49E34YUW,E[4\N,#!)'E[AS]WD'[D;E@R$HL%"-&S2_!LLSV; M;AM6I\5Y<*XMG"Z+RQ66QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2 M,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B M6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG- M@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3T MXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(? M]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I M^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE< MA!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=> MBD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.cvshealth.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports cvs-20220511.htm cvs-20220511.xsd cvs-20220511_lab.xml cvs-20220511_pre.xml cvs-20220511_g1.jpg http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cvs-20220511.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "cvs-20220511.htm" ] }, "labelLink": { "local": [ "cvs-20220511_lab.xml" ] }, "presentationLink": { "local": [ "cvs-20220511_pre.xml" ] }, "schema": { "local": [ "cvs-20220511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20220511", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20220511.htm", "contextRef": "i18e4d7505fe14d60a485991ad69917c3_D20220511-20220511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.cvshealth.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20220511.htm", "contextRef": "i18e4d7505fe14d60a485991ad69917c3_D20220511-20220511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0000064803-22-000018-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000064803-22-000018-xbrl.zip M4$L#!!0 ( V%L%248.&C*!T *07 0 0 8W9S+3(P,C(P-3$Q+FAT M;>U=;7/:2K+^OK]B+GOOKE,EX=&[1!)O.08[Y 1(;!(?^.(:22,0%A(K"0/^ M];='$H[!8(-M L0Z5<#_\9]SUT0\/(#?R/!:&("^@_1Q_^ MA^?__G3^%94#:]BG?HQ.0DIB:J.1&W?1I4VC:^2$01]=!N&U>T-X/BES$@PF MH=OIQDC$HCB7&):H:@B6:DH\%:G)R[:.>:*KF+<-W<'45+"@B5RG)$FZHE X/1Z-1<6R&7C$(.X>N[[D^9<,]C$/B1TX0]DD, MY#B$06 >B[P@%K)*QI$[4\E(2JH0,18._ZY]O;"ZM$]XUX]BXELT*[6HA& 8 MQN&8=:]PU[_%W1.Q(-WKXUU/X(?KY36SU%\UQWQ$K9G,\+W8"6X>';R@\%CG M)6%:CTU_#3[IWK022&"T$OXK3[,^Z-R]X6#ID"6;)*)W@X%4]Y'\,P0M><3O M?"Q0G_]Q48 IIL0^^M"G,4&L/$__.W1O/A9. C\&QN6;DP$4L])O'PLQ'<>' M"=D/C_[QCW]\B-W8HT?63<0SCL6*('PX3'_[<)C6; ;VY.B#[=Z@*)YX]&/! M=J.!1R8E/_ IM.^.2RPC#=./KFU3/_D(Z758/*%KI'[3DFI#NU>Y:9\9O4;_9[]U^4-L-VNXWJ^,ZK?? MMG MY]W&Y??;5N]ZU+K\/JDWCV_;Y>-1V]/Q5[$]:5U::NVL(K=ZUKC>K(QJS7J_ M7O[DMA+ MO=P1ZF7/K3>_*ZU^:]PH5Z&NFER[;&5E?D);BM]N!I-V[QBS/M9NKP5H&S?* M/W#CLIJ4;_Z>2S^]3L MWBZ876)9FDXEG;=4!697)PZH$4WE,95%4Q1 &>ERX<@A7D0?3.SA[%(.J4-# M"@(H6B" F# K18GDAZE'B>@MQ2!V/A8BMS_PF-1*?NN&C#/NRYKB.+*AAL/9 M*M+F?[69=2$*AF'R+9&6I8S;4M9X#K=-*Z*)0)E^PI]] J(=Q&7#%$>L4+#N>B=_YM+MNVDNR3E.FWZ>- M',X0:DK5.S(>WI/K3*88^J[/=RF#/R59+&K*('X_ M @5I)_3>A[4QOK,$\_M^"4+B$C#0EIXFFX% M7A"6_IE, G[OP"!YA_1=;U+Z=]/M Z?6Z0B=!WWB_YN+0+,#! A=)\T8N;>T M).C0P>3K*.VT!O4P-# =A""R;O^H5YN5,KIH'C7E1.?IQ7F]7* M!3JNEU'E[Y//Q_6S"CIIU&K5BXMJH[[%(8@K#>&21%W7[\2!SZ%R\:0(6%J1 MC0?=7LY*.S@MIXWS&MJ@NIS:*2G:VZ:V'$^U9?OR]+I]6>_7FC^D5J(%+:'= M[,CUWO6X76[AFEB3:KWS?J/\'33?3]G^_,5KB]Z-V1MXK9U4Z*\ MI-JF93E$LK!9.-+YO^8U'=I5OEIMKG68P@Q#4'0_#]<@@HJ7IA_=3FR8U!_FDT/L^"3N@TLP@CH-^B:FS&QK& MKD6\K)&DO30YTW2&5M2QQI1=#%HUMJ<-9WJPF.C!P]A^F*8K1<50ER;CHK T M[;%J!;$H8GG5:H$>C+0?"U)AB;6WL9R'"<'"944&Q+9!*93$P1@),!/WIMJC MSH.922?EM;G<*"IS;"[/LWF"=!@:8\QZ3@=!&*.#Z7=* (_1*$;TAOF4PB29 MVN]*=QR]G&:/$"#Q.&V+ @\6>HKU-J_JOB4HMY)BWP)*'3=0_3@NV? +WXM41BKU!IX"(%R])R:J<+@Q],'Z. M2A&P/!@7#K>BU>65M/K&G7WGM.-&S#T;UR%E+]?PL_'M;:UW+==A+) N-,H_ MA"O3LD5#@S7HZ+K&RY*)>4,G,B](AH850Q"I!:OQY.<%^EPY_MK\#+;?.:## MXV9B_"U9E[^=MU;0I0ES'53&!* ?8PFF0L,[5D D0M& 6LS=8B/71VX<(0"+ MH%'#=TO'E2W .!@DJV_[B!'T91&G.G-=R"@!MI.D5X>,FZQV-23Z?"R83N*; MP4*I>*SZ5A "E$SVK2YB #\GP="/P\E)8,\B([8-QCR+,1V$P0VK9Z\A4;M\ M"F*T,FDWJU#?^76]W.W6^E^ZK=ZG7N.RI0"\ 6CS8U3O5>OU?SB MU7KUZ_K9=PRP:-+JG[JULYK29B+WLBI"/\5: HF.YYWK%C45B:J4MPC(7]FF M (FH:O/4, R9"H9B"@X8 M0C(Q(N\*^_!.^_228_=3T*M9L@HG.&?9IA'^P& MF5@EHF99O(:)PSQD(F!XV^ UQS0%4;<=Q\%L2T/@L8#9WD+.L2_DV"895[/] M("L1S3G[KLR^U7GV5271YL.$I6/@A %<9>&J#<,W%-\MXO0Y5P0T M5WB*()B1XW'ORDNS+O;$/+K_\OMUQ>_Q(N3?*H7OS %ISF]QFG9FL M$_C8")O!:#]-J!=-%;ZR94?6-8GRJN-(O.Q0D]<-F_"8$$JI:=JV*!:.+H/ MCP+KFL;;FZ=$/3;";V#QNLD9RC_1('[);'9&5]C2#*KK.F\ZEL#+)E%X0W? MG*6FH0BB(BLF*1R==P.;HFKD$=^>G\]__5-0\?N7__U=7/$M@&GWVNX@=9*\ MM2D?7ZE8TE73H;PHB+" =<'@3952'INJ*5!%PH9F :(6=4-9]=#$[W<.9Y/) M8.X@A-7M#HB'Z)A:PQAT _P,T(A&[UZ+.0^ 7Q!CF(<.YI6.C.&0[>D,$V1$)*8"G:M(367L\9+;:" MVPXV*$V8^C\&NKQ-^3&YDJBNL'L?O&E3 U2&"U71=LC3=U*A2.)+Q M U?2NTUJ_J\!F&K?&!OOL;?E13-S>V4K%(BF.[QNZC8O8TOD#9DJO(4M4R.Z M:)B.7#C25(47%/S 4_)0N.^<]#H% <6<+HG&"9X#KZ25!> W')0>FC,1A%# M?,@CT?2T36DGY53]\'@]A;(EPI]TJ76-XBY%9 " &50N\SR9P1B9U M&C/(L MDB2F/HVS$@-LW(,Q+O,%Q25-D3/8QBRAW[X+M.&J':Q M[.0$7HF>&Q2$EZ$; \F9>VSH9_ZAZ*'M8P:!9Q*@7PRS^.:$I25<:5B1B>IH MO((U=B>36CQQ#(=794I407< (AL%L&X,39;?+_,JO^ZIF]5X!Z'?)+(6-Y_Q M%_#L?09#@WLG?,^''D6RJ&0K-IX]VBA(N0<4U4_>EC6)-P5=Y4U9) !V3*Q;9KYB M%UP-NF,NU,^XZ^%R%63""^*]%3MS /]NOOF"EJZ(+$O8MF5> Y*# M+B:4-VU3X"EU#$HE29 ,NI,+>@NF_VLM;8GR\H&UVM+.\FYJ:;\R0/EE'*3F M/@VI/4. NSN#B6S+S'\8]$-K?V?/>QMZT=#49QWWEHJ:8KS^#4&]J,C*JU MB:(5CC"](?J$)-F.NICTS< [B%8YX+42=<*TD3^:>/7L!DW"6W2J,4"8CKHN M_/)+XJYS5#(C4"8 EQ+P#?#F)KU"J5Z<"**92(B]!)I9.*2SFEAO?O+8#F*- M]:])U2[=Y1U)5P=2Q M1C6Y<,0, %@3%W%@77-H0$)T0[PA1?^+BUA Q85J/N\"QWY4OD-2R73$*F" MR-?)"NODP441+$JFKI@B+VB"S,M4==++WK9JRIJ J>VP??V3GQ?;6@-O05G_ M!FTR-1K3*]7SG@T&$/;X..3O7D4/[JM8DB.+CF7PIJ*KO*S:*J_#[/"&JIE$ M%TS)4 3 9, NK2"\3O7-G1W_].65'3LUO]B>K_HVZIS&WKNQ&"/E(8<8=A_$X8C.(N\X8,V%8_B9!-'6@BN>J=[BQB9>H"F-M6 M3.,$2>B ^7>T]\GNXC2SFUP2'[!+XNSL2.I2$4U>7%#7HN!#=Y4R]\JOJ M+>YR?"*CJ"O2<[P/AE(TM.6N@,?)70\2@_8O6[AQ M5AO5SRJW];.?H,.NA4:Y-6XW*U+KLJ74RAVIWGN@R\3:V:G7[GV76[?'&/0= M;E]^Z3>:/Z"]4Z_6M+M0SZA1ML3ZZ<*KPX:IZA1FA]<)I;R,#0$^:1IO8T<6 M%,<4%/7I7;M'KJ.QX'$;NX_V?+'1&T:QZTQVZ )@U7E$1;+SV@OUK?O@!%T7 MM"GUJ,4"VOM!XED?1C3)!=]:0?G0@T/@I1=2R'U"+O]\2#X M\"^4E0 F_*L(,<%:',8/BSP5KWC=N,G:7=SD;OB+<3N4-T-*KGGB "@L$6]$ M)A$+^;6QX,K,QN-A@D-BQ:5HV =!,=F\5%L2LCA;_0KBT4EV4YVBLP 6+!,E M%*2,C6K$!S*Q#=(=V\I[N9ZE3$@=0'JI1$;7OG\9LSA[!)F*J2FR"1_2&-AEX< ML9V&9.NAGY 18PN<9R>"&?9(V8"=U,*,*HD SWMR/5SA3[6SY:>W%)#0M M._4>1( ELQ/O;+ VC:S0-5/3U*8Q<3WV*4ZSCR]9] MUI?C00B%%G7F6U+#Q;2&F=Y VR/V9P T9K4O'#_#!4R%1XP#0];V#6&>L:1K M7%+@'M4%3I ,3M-U3M:DU-<=337R/7(G-\:LU%<>I;YRP/:@7>)A0G."_CL, MPF%_[UCY>#$)!0& $HA@"DTQ'&2[(4@M^)#0?XJE,DZ>I].G * /(V(Y*Y76 M01"L@S[[G5VZ8P%*T4$B-X2,UZ;\,>4Y!N&@)D;?!-"1>Y$?LBDB@T'@^G'" M:_!3)80Y0?\B_<%[U (PUD%?OWYCOI1%W634']!D"F;/7Y@>F&[WT)SC0K?9 M"%)F3?HLOD,CJ#>Y%G)#[24#8&(OS<$QKH?Y)3; QB"<()-$;I2R(P.9U(]F M!C;?668'V@]N>@)EF:/(C2POB-+UR K/K:&LR])\ET]91??$T+W%GI2(D,PA MA4,JAS0NT4KZNY0!&(B^J^>%+/^,R./[$[&P*$OBZQ\U$3=S,$8HJL)&JA7T MYM6^RC&>G8C@??=:0U)AR8VA,>O)8&%I7VUJ92"DE!R]8[E2I+>& M=;J&&V.[GLS7I]1I$.Y-G//7'_UQA[!7W-XR!4S P6P'YPW3X%,87 .PJ <^ MSZR_:*VS5L2Z[H0 PFP^&YEE4>HXC^UM+Y*L6W1@"JLX\EYKG%L^J]C-[ *7 MO6/$T#*@_.09@@3V ]1E,4L2LRQ*;8OD?5&6<5HLQ;)3DV$6"'-)^&L:LP)@ M(6= =QXESP%?;@;P3LW07Y;[#6/)51ZC>'**5E!S^UG'VFO42?Y[68?FZLCX M'R7_&KN^$$X3-YX=H./.T W9T;DE["6N1P&,]F.KU] Q)\@:AW5U]KK)'*!> M:]KQZH-^*W26.4,6.44W>V_( M#BD9CM^><0<*3Y) &N?&W6:-.T$1P+@32?U76[<;?7^ MO&]-^&/?1S6F\KZ1T'N>+W./H9JAB9PL8F!?/8?$FQ01(F?(@"J4W/+8K+[# MNL9)>L[,NZGO 9])^1DWK!59RB<+N5;T+NIZW*K;IN!9^P1NXSXI8B^#NV1 MVWES=ITF)T.=_>V"2=-4X3!4Y2/BNX+)3[_S:5A2%'-];S ?W-FG2)QBFP $L[MC4W261(X5=8Y M8>TC\3F9US3K@*&%;9H;;X#*N5FWE]JN1L()^EI$%RS@NAL&;\ZPT\'<,&3. M,)0<#&]2UW',A);%G,H;WJW3-##N\IN,NZGJ_ M0;M.$SE5DCE5R+?K-GSA0!$U#J]] B@G\YIVG6YPHI@S\VXJNQVRZQ:0>L>" M^8EO)YC?HD#62?CMR9:B;F\L_-_RZ']_*C)F=_B7J8(=I&\]F+LA\%*S=OZ>IM_P MDQ4[ILOW&/@;6.*P*'/*VN'G<@-K'3KKF-,, $YR[BW8[ :$*BFRP5[W_3%5_^DK9LW'$_?>KGL(2Z8.2;\28D@6-TR0I]PUL MF,Z*RD)M2)R \XA'&X84BLR)8NZ"V4U(L4.[[;L/*92WXY98B"9FGP-];&,A M?8'TI$O<\#>AA#=B/(@L"KMN<)J6&VD;O62E @Z394Y2\INN&_6@<5A0.4W) MXT3M)C[(70[KO)*1NQR\9,\"6>Z-"WB!Y8V2AZO]P.?9,]FAFSP\F#PV.+1= MA@JL(7LY&W[('J!/L\)H(YH]/H]H?^ %$TI?LG61NQR61T3499T3U1W9P/U# MR6PH*J?H\+^11^/:,#LS2('%G,R["2ERE\,Z=LA67 Y;@12/^1V2W0BFIP?$ M!=9RK6OD47)#DPT.XGE[@!#VV'P0620,=EI_;9F:FVEK+7;!X'05WW MC0H+1088ASDQ?U!KL_P,["R*+/)O3N:=A!BO[84XC(GIT:G8AC_3IK/^RF)1 M8V,"=>4R]WD[9"SEV;],42J@EHG*;D8N@_[KH1.AF& M(3O1='YG5)P&81_I_%\(4DF4P?>HA-8;XG1P&Y?.*R_B>KGR-VHV4.7OS]5/ MU>:"X20J[I=Z"H''F#KUR""BI>F'][8;#3PR*;E^TDA2Z#UHH@X([4RGL1[- M&]",#FER)LL-HZAAC8GSS'S/&LXD?3&1]'-Z/DV3BX8@+$W%Q>5IC]6J%84- MU*K+15735ZHV6AVS.! MHEF&+@WIT&>.558=&<;=((31V0_AX5-\\ Q4]=O1BZY(ST(O:E'3M%<'&E)1 MD)57KS7I[$O@B_2GPI?71SI;1@8_+]#GRO'7YF=TTCC_UC@_;E8;]46!2>9F M6%#V:HIW;#(6^ST!C]$2JI$)$E0N"="UOT!T\0@_39;?[=G=(255EMP8FK-6 M&.1A=(A.0/-0ZK/W@&L68.X@ZBY:5+]W 67J$6RK$O.* RYV;30ET:X1_8GX M.CM(WKVBX 7UW2!$/UV+HF\AC5P[V#*D,0N2GU-V+8XIZB11FE:0;'N$G3:7>/]*:,S^VL&]@3^Z<9][^C_ 5!+ P04 M " -A;!4I$@+37 " "!!P $ &-VQA M$(ATSO>=^Y'/SG=UA38@).5LZ?A3ST' 4IY15BR=VYLKO'#.5Y/)V2>,[[]< MK]$E3]L:F$(7 HB"#&VI*M%=!O(!Y8+7Z(Z+![HA&*\LZ8(W3X(6I4*!%P2' M6A'#//+3>1)B""#!LVSA8;*8>SB+%KD'R8GGGP:?BS@,%]')C/CX-)IK6**Q MR2F$>)%'I>(:L"'KE$G1,( 3S=CV_I> JE4.4UY[9ITO1/?=Q!1 M2M"D57#%17VI0VTKM71:]MB2BN84,EWR"DQ11X!G:D5$ >H[J4$V)(6/>%U- M$#+%H'7#A4+L56Y?#3^*(G=GTG-05[PU3XFR$_%F-2P>FR/V QSZTYW,'/=# M;L>&*).*L!2.\:UO>.#]BQCVK3TNAH%W? S6F(1T6O"-FP$UG?,?9Z\'(-\F MF"/NCF//A#&NK TCZ65-0UG..X$6F?#C(8=KR(>=>;$(KPR*_8N)2 6O_C)5 M;B-X T)1D,^7R!HH!>1+1P\Q'D;W=T62J0YD0+RP/^Z#4;N: M5ZG\C 54^- MYDK=A0JZTOS'>3<"CLU;4Z1^-VR;CTS?\&^T'M%LZ5QP_0GX20H=GI'?7G]] MYXVQGO>,P>Q@.(.<,FH'S]//K/XAO/]L8&29R%#/W$/"@:E60O:#K>SY,-6> MW$/>(::D2MOJ>-X^K#=IO7 H9;]H[GC3NONS;;2";LU7DS]02P,$% @ M#86P5$?_\BG$#@ ?@\ !, !C=G,M,C R,C U,3%?9S$N:G!GG99[.%1K MW\<7QFF0)B&AB40U#CO'0F976TC8$2$B4L9IDF1DF!PGQB'G(DV%%";G0PCC MN$N:\% S- :A@\G,3F,QIW<\U_.^[S_O'^_S?->]KK6NZ[Y_:_T^]_=WKW4+ M/PH9P/;3IQQ. 6)B8H"_Z "$T\!)0%Q,;*O]2Q*2$EN2@D D)*6EI*6W3AE9 M.5D9&:B,M#14 0J5DQ=)6G:;HH+\MJW[K8=LA6]%B9J\C+2,_+\M82\ DP$T M@#(),6U '"8F 1,3#@!P !"3%/NG@'])3%P"(BDE2@DJ)QK0LEV4OH2$N"A9 M20A$U!LOZ@<@,,D=6H>/2RF=O22M';G3.#'WL1(P GP%81 4H<0 M(%_PY^.;[W6I,OY:^87.\&Y&&.M_"6IY3YK>Z_+;3.?G,)B&EZ9?G<>HU.=N\ M*\EUE*A1DH!_ M6I!_\8-.S@U+'WT,< /U0$KF_K*\\\[#>YBB-VR"X7!R'4<8F M+S3YS364+ M$&GLVTUMC\:FGL0,4$P*,O(N* M?DKQ>('R--8\F8M93,%=%KSS:T4?YG'K]\^V+<^H@ZE8] N>,C\/BUR[:K MC4(>]PMV2/78W)D(PW-L+^VJW68%L8S2I.1B!*<;%=+%_+F)YX2*G"J8Q3J( M+N[?_31XMBH$(2!KE+K&=_^%0/BS:2V?:M[LO2,58%?R9":Q_<&HGS)61U0. M*0G&=@ST+K!TL 2>9.9X3%<]W,*QI:'^X<2[R1S9]BCFC4/LV M]QFBJWY#8FZ8&17%$ *@WH8B MKITHX2(X-T49^7[%J>,8V;?.W*I*;T9+8BA##_?F#]TRW1S(G9YV6!S@U!_7 M&N*D.:+I26*70V]/>XJ37FOTP](_G].+\&Q=G5R)ET+"] MH:)L=L5X:0B--CI(XS0,$D%]16;^U1Q='H#[56M==[3?TJ^420FU939QV42 &=.5ZL9C+Z2L\ M.8U\)_/R.?X)S9C^<;&!_'N*I;OE'RGHO'^\L>UF-F(-+9 I$U6Z]A0R?%8& M4]??;3B^5HK>B3F%0-&X3LDK[)#6B=@[FN60E,+=VNHH*/G],[][AAO.QN4# MA]R7-DJH)'BYM=_.=C_#V/T^"2XIC[ZZE9RN5#,[\'1\\<'NR;6(=2>2PBRH MI<=$LSLYF_PL4R&02519%6BVWE](RQ? F!;]M]Q'RX8>&!BAPWZDCCB9UNC= M>__'UR;U4ZRHW+:T4LYS?HTT3Z4#3EW!$!@$C(J+ J[OG1*NSPK'?X2UXK>' M(9NZ*,TKW)@\V9^ML7$OIW,*>*+5"P% 3:X[9D0@NY]%= 7#V=_G9I-XJM'\ M^AM,=5H_KU*A7R,,[EYZ^ZY39.!+]:" 2*ZO% <7*+(L&O=3U'H(7IG%4U+1ZNTG@R+AU;J M-7=*E&]8Y5FH9S16^,,[3Y9LE N@<^RF^>*5":X\V#]OU^=[DGS3]VN [Q?[-F5 M0-:LIQ# 2PEF$LS9](9:#'Z^<$U@R%J_$RW[*S2=I,/=&=1*CAC]? (R<>9X MMLY^3Z/?'P$)#U XEJN!ZAQQY2O7""3,*Q=5ZMWI":9:(Q_3<)>\)%#A-2$> M!R.+%0\$,]=7@:53?]I)0[*-.'?Y+P2'L1#1C/4F4)!0VL_>F!Z9;JNLV'UM MN\\L^$P0'<8]%M=G8NEN^OEO4D\,F%??O>[LTN_7UK82QZC+@$-PC/O=.I/Y M P;/,2/>+,5D,V3C]P^M=[L?TE %&V<'#]4J_0CD@DFCF0#CO,A:L@CNLIQ3 MG *$]7<(F@QY[<3T]F[J?\G.'W:Z;S39%5X@*:E)L(E]%[1CU.HE/QIG?=J MCBI[(L/RC@+\*\Z6RS;XJ;(''SZO,WVYNS 6 AD26PAPPL$LKG5;.E;I$ALQ MOY3#6A@2J!4/6&:3*C$/*>>4TEX6&B[?)3R#Z Q\ZQ5?/BJAL-FSAV$3 F1[ MRC%!6.OY72,;BH/_7 *W7[K[PLWU=@:77?NAZUE;7Z524Q+NY M=-RRBN@T>2L$@ORH;F0AT#!+9B+)%V4G$OHKJ0E_HX+Z?6;?17;/QP#H0I8Q M!I!TAU976X<*H#6BF7G;(+($S].?F!K:5% V7,3':LA#J0B!U!]?'H M;@69/X!&8P30?]UBRM3]7-]XF9'_A\Y0SX41,-^8O!1ZY+$[]\;&R]+.\-6X MU7BW[G6D-(6W0X+S9HQWU**_)H[PE&4[,%W9A!^*NW$P/7YQ]*6_L]_RT=L[ MJ$<,,@59.+)N#Z,8R5K%X3O6Z'LG]:-7-<#V 3-$J1FNT:M_.\Y0QO'V6PG[ ME7?NQ6?97IN[?FOGH3C[3]W%4W0\+=*"<'\I)JG(S]>MROGZ$K$I MB5#J,>7RXCDW7)=4U?CM1U:5'?0/%\C3$^/ M;?Q1E&$.30C,2^HYB60\@K,%$X8F!5>7%UQZ?O"9P?Z7E <8TL#1PC/[PVQM1U/! MW;XWIOS>KI#J'->1T# D(W^VM>HV#_8,:S(>H>=U_H//17RVWX/(X1X-:X\I1Y7B MV&\;T-5O;DN:?\DIX0 M%([1VL!+$ *I.%:-0'D3&T["!;LDXJ95SPMDT[X/!?9M MKB>37CQ%+39VH!@EB&>!178'M07L])MA4O;E:Q^%@/\J@=BZNH)BY_<*@9;S MF5AD5"0[S2S'B;6<&I;;G(.//)EN8$.QLM,<7>Q[=Y>"A:%NGOWJ052[RD[IH:Y"M;5]?5 *$1%7 MNC[*V6AJQ\:%_86VY*?T,/)P&MV*.+()+GB5BA_ZL$D=ZN%B2/.Q?\2'&D[@ZNOIAYC!W'D>.7KJ"M M][&6[4 25Q] :Z"QU*\[NIP5!UMU:S,6"ZT\V9NV+O) MEEQX6 9\]'N+G?*FERV A8OV%!7\XH1C"5/>=60K9$JW$LNPH8)W&$RLX#F\ M?/G!VLZPU&"0_N#G2@.L=H>BH6V!DB'ON4^8-8S3T]\Y&G66M8<0.>]K,^S M5AY,[2JI+"RD=K8T=P;_8U3#M7&?/4$KZ/R!RJ0T6L5= 4 8W9S+3(P,C(P-3$Q7VQA8BYX;6S5 MG&%OV[H5AK_W5VC9EPVXK$5)I,2BS467VP[%>WG\(@1\_K7AYN9]T.4\ZS(WYS E_Z))_*T MX%E^]>;DZ^5[D)S\>OKBQ>N_ /#'/[Z<>[\5Z=V-R"OOK!2T$MR[SZIK[QL7 M\^^>+(L;[UM1?L]^4 !.ZQ>=%;>/979U77F!'P2;ORU?"4Q@BED(1" 8B'CB M YI@'W"22%\PY,,X^.7J51@F!$44@IA@-8RIL2P6(4@DP2*,A*1P$726Y=]? MZ2^,SH6GDLOG]8]O3JZKZO;59')_?__R@96SET5Y-0E\/YRL1I\LAS]LC;\/ MZ]&0$#*I?_LT=)ZU#51AX>2/W\\OTFMQ0T&6SRN:IWJ">?9J7C]Y7J2TJCW? MJ\OK'*%_ JMA0#\%8 !"^/)ASD].7WC>PHZRF(DO0GKZ^]NR28]Y!](;[6M]0#BZG0_'DKC+D\_'DSNI:H/XOB"UZ;I+7GQ@7J7 M\Z$^NT]3]99^?,6'^E@4%9T-\+%XGF9-\DP_<:X>+:?1@784TWJ>9>E>DRH> M*I%SL:B6C=!>QM^WG)=B/E]^4W,+.$UIC&-,": BQ2 * M@P@0+F) 8PE]"+E:OMBT>OI@3T4.OEZL--03&GS*G3Y[3F5' /\7Z8=@ M\;#&;W?DR=8;^[9<::9ENL?[Y8A)6JB^Z+8"C;=!]Y$6R56%Q6=B8:>:_L0K M2BY*U?.VI-+XC'XNQ5EQHYK>5.C.]\-\?B?*2UTVRD]2BG(:TLB/:12#T \E MB(C$J@8P"E $PY#Y(F%1;%H#]DTVME*@]()T3;"W4.PM)'NU9O-RL-?J_57A MD 8>N3CT\LZJ0)B:XEPG]DXP6+DP376]:AB_QKYX- K2YT)=",[^G=V>%5Q, M(\&ISS $":.ANJ:E$E H!*"!NO!E$8(8!4ZM0V.:L16,S15Q(=93:CTMU[%U M:#IKV3LX^S5P\V!JE7OOT.K$89J'9NB?TSVTIM?9/K2/=BT!7\15-J]*FEW9AC"35UQ +L]]9Y(;P0=&.;VE+8Q[AAG#_"W,JLJD>L6X2[/%ONV\ZD4 M$4QC#@'VU9>(A %@V)? IY %..6A1,B4X-89QH;P4J375&F.<+N-^QGN;=3",=R:USO'N@?8@ZS^ZS#Y?%[GX>'?#U.4D4\MMRJ$ M+(Q3$&&" 9-8@% &!&*",&+&+?AF\+'A6^OS:H'>0J$YNEO&[:>VCQU'!M;" M"2M8NU)VYG0KX&"(=J6R3F?G&'LP+XI9EF95EE_]3A4+&9U-)1+,ISX!6$"% M9HP((#%B@)$XDFQ$Z#($JQ+Q(@4C\"48 P2&"( M57&_9G]6=8B;/:E>.H72CR@,$$@$4ZNMCWU $4,@CD6"$XFD#+@I M<.N!QP;3-+W@JWMDR=<6L$&PRWMA36<6O]O3MN M3S?[_:96SBG!)!1"Q'H/V =JS:,@"7F@+E)E!)$O*0^-]X]:9Q@M@ N5GI+I M:9WV+#:--(?2V9ZAZ#1UQ@G4UNQ[$]N,.CBZK4FU,=P^T*%9+7Z(\BW3?QQ* MJVG,@D @& (90+5X"C\&E"4$H)BQ0%*?Q"$U[E;7(X\-WEJ<]Y^5O/]:-*P- MPPPZ5E<;CMVRFCI@U[2V9>O>M3:B#=>VMB71Z%M;!_3<0-+-\*?RLKC/IR$- M0U]=&X(PQ3&(9*COJ0XXB%.!](B.'W+>(MCTXS.[06MR?LS&TG5CGGE#+4%?(S]2:7=+9AYR+ MAW^)QRD4D$=I' &:(*YOF="7J2$&*2,$1BF-.+8\++$QPT@!7ZKT:IF>TFD+ M]Z:1IFCWL&<8L,V=<8"Z(_N>2&]&'1CHCJ2V<>X:V/L 1./H0^PG7*JV65*I MB$8\ 90'$4@#$@N*PYA2Z'CTX<]TZ.$@IQUZG7/XDYQP./K1AB,>:AC#<0:[ M@PR'/,+P/IL]W37%(D05WVKQAD)!CP- 840!07$4(TEIR*7=,OXW%N&6,/YEO%.->< MOY_1JRF1/F<)C * G7]'"(!$H(D$ $3$A&(86)\"K$1>6Q(/HGSM#IS')MV M[6?1V80C@VB8OQ6$K;DZ$]B,-AA^K4FLL]<^P!Z\RY+J?Y!S\7C#BMDTXES? M0YP EG#5 T,N 4D3!D(24\8$H0DWWKAJ1!X;>$MQWD*=.7A-N_:#YVS"D<$S MS-\*O-9O 8< NLVHFIHE &/$8 4AE MK-=PM7QS"0&7/H$QI!C'QCO.F\''!FXMRBND!X._L;][*[GVY#ZY9TZMBR?' MONBVM,,)V^/Z%'!P5#=3:<-T:XQKL_TA3XORMBCK!KX^3'16W.55^5B? M;$EHF$A*.$@@).IZ/$CU:4 *. HI53TW":#QC94&\XT-Y&5#V="\=M)MJ=SI MOU[M]MVT(S^8F\-TYKV,=&C3C>SIV:[OGF/@MMTHX>WVW>QE725F_1T[5X]. M7ZR>R1;_U_STQ?\!4$L#!!0 ( V%L%0Q9)4>JP8 $4Q 4 8W9S M+3(P,C(P-3$Q7W!R92YX;6S5FEMOV\82Q]_]*53U]:RU=^X:L0O730KCN(V1 MN$C1%V$OLQ(1BO0AZ=NW/T/:;NS8:0E3@)D77:@E9_8_/\W.#OGFI^M-,;N$ MNLFKS7ZIPL8&RG1W5 MX%J(LZN\7<\^16@^SU)=;6:?JOIS?ND(.>A/.JK.;^I\M6YGG'+^]:_U'FC+ M@O:" =/9#24.*,IB=8D"EY1EO'_K/:$,%9)QTAF-0[S.-9G((A)5H.0D!R[ MO6B1EY_WNA?O&ICAY,JF_[H_7[?M^=YB<75UM7OMZV*WJE<+3JE8W(^>WPV_ M?C+^2O2CF;5VT?_Z]] F?VX@7I8M_OSMY&-8P\:1O&Q:5X;.0)/O-?W!DRJX MMM?\7_V:?7-$]XW<#R/=(<(X$6SWNHGS@YW9[%:.NBK@ Z19]_['A^-')L-E MLP97M.O=4&T6W8C%484\G+I5YV]_?GMS#OOS)M^<%W\?6]>0]N=X-NGB2A7K MC?[XY=S%%_OG-32(3#_?$SQP=XG.V M]@>L6R@BWD[PW4U3AT:"BD[BJ[\\L MG(>B/[J,D"_[*Q_ZIJU=:)'L?[+[2&X_]L(\,7DKT,M\O_\3GN'8I8T*@L6_C A& M$:F3(]XX33('*O#(I)9JM.L/+3[V_&%P#^LPJ^H(-6:2>Y.N#D\"_9CBNQ&+ MU;WP'U%_.*HNRK:^.:HB+*/SB=%.#&<= M3H=:XI1#S*7D GA(0HLMP?&/C@QB14Z=E>UI/0ETWN4%_'ZQ\5 OL\QQFDPD MSL7>8T4\MO=R=U$ M@LHDE=R3I 5F09EEQ'(*A#J3&>9U ".WA,,W7!C$AIXZ&]O0=Q*@',:((6CN MWG!/!VQI'# +'? M"2!CU)T2):=5T[KBK_R\+Z4SB[4TIY'$S&1$9@B\T1:5"I9)SYU7(MLN(X_L M#VMXT>\$D9=+^\J =,GOL ;7^PV.9IY+BB53HBB%#<0R80BNC)P%*:QFX[N> M#RT.@V#";<\7R_?*8>_NE!2GZZJ\WU99(V.*CA$&6;?R:5SY,+T1 88ANH8Y M.KZ:^-KJL/!/N-LY2L971N!3G;M M(HD+ARM9QHF7D)&@1:9$])J'\?O/IW:'L3#A7N9(*5\9A-,:.HH!B]W^GEYW M6[A^GU*7X)Q4F72&*)^A(("[9V]=(A%TS&1F!%?C2X1OVQ\&QH3[F5N2=EJ M'#?-!=0/Y\(U%QF5&=$A!I3'6.)8<"1V&R?-9";C^&7DW[P8!LN$&YQ;E?FU M%Q<(%[A WC#NS_*V@*6(45CI',F"1]^9R(CW7J/O0O&H>=)T_.V0KZT.0V+" M+UZQZ!^WBS\56Q5-0X,)21)!@Z+I4F+@1&0,F,4\9EL'%T_!^9 M'!;\";P!N M:PG@H>5A'$RX.SE:SDET)=]NH%XASK_6U56[QH7NW)4W^'MRT6&%['CWJ)#, M*'&@#(G):,HSW$3%M*6VY+,.#'L :_)]R?'B3H*1(Y2L=L4QECS7_X6;I4E< MZ2[G12DCD8E)XJ*DA.I,6Z>BI6Y;3>NO3 _C8L*MRO&"OC(1AU@#QZX.?E>X MU5(F+2*%0*R10"3F/F*R@*IPK8.23 B'>" M!PYV[G[H7KKG[@]V_@]02P$"% ,4 " -A;!4E&#AHR@= "D%P$ $ M @ $ 8W9S+3(P,C(P-3$Q+FAT;5!+ 0(4 Q0 ( V% ML%2D2 M-< ( ($' 0 " 58= !C=G,M,C R,C U,3$N M>'-D4$L! A0#% @ #86P5$?_\BG$#@ ?@\ !, ( ! M]!\ &-VZ8_QVP* M "E7@ % @ 'I+@ 8W9S+3(P,C(P-3$Q7VQA8BYX;6Q0 M2P$"% ,4 " -A;!4,625'JL& !%,0 % @ &'.0 J8W9S+3(P,C(P-3$Q7W!R92YX;6Q02P4& 4 !0!! 0 9$ end